Macquarie Group Ltd. decreased its position in Medidata Solutions Inc. (NASDAQ:MDSO) by 70.1% during the second quarter, Holdings Channel reports. The institutional investor owned 25,362 shares of the company’s stock after selling 59,587 shares during the period. Macquarie Group Ltd.’s holdings in Medidata Solutions were worth $1,189,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of Medidata Solutions by 8.0% in the first quarter. Geode Capital Management LLC now owns 384,076 shares of the company’s stock worth $14,867,000 after buying an additional 28,582 shares in the last quarter. AXA increased its position in shares of Medidata Solutions by 0.5% in the first quarter. AXA now owns 148,700 shares of the company’s stock worth $5,756,000 after buying an additional 700 shares in the last quarter. State Street Corp increased its position in shares of Medidata Solutions by 3.7% in the first quarter. State Street Corp now owns 1,154,085 shares of the company’s stock worth $44,675,000 after buying an additional 40,827 shares in the last quarter. Royce & Associates LP increased its position in shares of Medidata Solutions by 20.9% in the first quarter. Royce & Associates LP now owns 188,165 shares of the company’s stock worth $7,284,000 after buying an additional 32,500 shares in the last quarter. Finally, Champlain Investment Partners LLC increased its position in shares of Medidata Solutions by 18.7% in the first quarter. Champlain Investment Partners LLC now owns 1,412,460 shares of the company’s stock worth $54,676,000 after buying an additional 222,435 shares in the last quarter.

Medidata Solutions Inc. (NASDAQ:MDSO) opened at 55.50 on Wednesday. Medidata Solutions Inc. has a 12-month low of $30.22 and a 12-month high of $56.27. The stock has a 50 day moving average price of $54.23 and a 200-day moving average price of $46.29. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of 142.67 and a beta of 1.21.

Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Wednesday, July 20th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Medidata Solutions had a return on equity of 10.32% and a net margin of 5.29%. The business earned $114.60 million during the quarter, compared to analyst estimates of $112.39 million. During the same quarter last year, the firm earned $0.22 earnings per share. The company’s revenue for the quarter was up 16.8% compared to the same quarter last year. Equities analysts forecast that Medidata Solutions Inc. will post $1.01 earnings per share for the current year.

A number of brokerages have recently commented on MDSO. Morgan Stanley reissued a “buy” rating and set a $61.00 price objective on shares of Medidata Solutions in a research report on Thursday, August 25th. Deutsche Bank AG boosted their target price on Medidata Solutions from $56.00 to $58.00 and gave the stock a “buy” rating in a research note on Tuesday, September 13th. TheStreet upgraded Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Thursday, August 25th. Wells Fargo & Co. cut Medidata Solutions from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $60.00 target price (up previously from $55.00) on shares of Medidata Solutions in a research note on Sunday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $54.09.

In other news, President Vries Glen Michael De sold 7,500 shares of the stock in a transaction dated Monday, September 12th. The stock was sold at an average price of $53.70, for a total value of $402,750.00. Following the completion of the sale, the president now owns 950,153 shares in the company, valued at $51,023,216.10. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Tarek Sherif sold 22,036 shares of the stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $49.24, for a total value of $1,085,052.64. Following the completion of the sale, the chief executive officer now owns 877,580 shares of the company’s stock, valued at approximately $43,212,039.20. The disclosure for this sale can be found here. 6.70% of the stock is owned by insiders.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Medidata Clinical Cloud provides a platform of technology and data analytics solutions designed to manage activities across clinical development.

5 Day Chart for NASDAQ:MDSO

Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions Inc. (NASDAQ:MDSO).

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.